迷走神经刺激市场规模、份额和成长分析（按产品类型、应用、生物材料、最终用户和地区划分）—产业预测，2026-2033年

预计到 2024 年，迷走神经刺激 (VNS) 市场规模将达到 5.5015 亿美元，到 2025 年将增长至 5.9581 亿美元，到 2033 年将增长至 11.2755 亿美元，在预测期（2026-2033 年）内复合年增长率为 8.3%。

迷走神经刺激（VNS）市场正经历显着成长，这主要得益于多种因素的共同作用。其中，人口老化、技术进步以及对VNS作为辅助性治疗的需求不断增长是关键驱动因素。癫痫和偏头痛等慢性疾病的快速成长，以及这些领域尚未满足的医疗需求，进一步推动了市场扩张。神经系统疾病和文明病的日益普遍，以及支持创新研发的研究经费，也是推动市场成长的重要因素。此外，微创手术方式的普及也增强了市场的潜力。儘管受疫情限制措施的影响，近期患者数量有所下降，但VNS在治疗癫痫和忧郁症疾病方面的有效性使其成为重要的治疗选择。

迷走神经刺激市场驱动因素

随着老龄化社会的加剧，神经系统疾病的发生率不断上升，对迷走神经刺激（VNS）等先进治疗方案的需求也显着增长。老年人罹患此类疾病的风险更高，因此迫切需要有效的干预措施来改善他们的整体健康和生活品质。这一趋势凸显了VNS等创新治疗方法的重要性，这些疗法为神经系统疾病患者提供了症状管理和功能改善的有前景的选择。因此，为了满足这些不断变化的医疗需求，迷走神经刺激市场正经历强劲的成长。

限制迷走神经刺激市场发展的因素

迷走神经刺激市场面临许多限制因素，其中植入手术和后续设备维护的高昂费用尤为突出。这些费用对患者和医疗系统都构成了巨大的经济障碍，可能限制了部分潜在受益者获得该治疗方法的机会。由于并非所有患者都能负担得起必要的手术和后续维护费用，这些费用的经济影响可能会阻碍迷走神经刺激疗法的广泛应用。这种经济负担是影响迷走神经刺激市场整体成长和普及的关键因素。

迷走神经刺激（VNS）市场趋势

受患者对便利、舒适的治疗方法需求日益增长的推动，迷走神经刺激（VNS）市场正经历着向非侵入性解决方案的显着转变。这些创新设备透过减少侵入性手术带来的不适和风险，显着扩大了潜在用户群。随着医疗机构致力于改善患者体验和治疗效果，非侵入性VNS技术正越来越多地被纳入各种神经和精神疾病的治疗通讯协定中。这种日益增长的接受度不仅提高了患者的依从性，也推动了市场成长，并为VNS治疗创造了一个更包容的环境。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管环境
• 专利分析

全球迷走神经刺激市场规模（依产品类型及复合年增长率划分）（2026-2033 年）

• 植入式迷走神经刺激器
• 外部 VNS 设备

全球迷走神经刺激市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 癫痫
• 忧郁症
• 偏头痛
• 其他的

全球迷走神经刺激市场规模（按生物材料和复合年增长率划分）（2026-2033 年）

• 金属
• 陶瓷
• 其他的

全球迷走神经刺激市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 专科诊所
• 门诊手术中心

全球迷走神经刺激市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• LivaNova PLC（UK）
• ElectroCore, Inc.（USA）
• Cyberonics, Inc.（USA）
• Boston Scientific Corporation（USA）
• Medtronic PLC（Ireland）
• NeuroPace, Inc.（USA）
• Aleva Neurotherapeutics SA（Switzerland）
• BioControl Medical（Israel）
• Inspire Medical Systems, Inc.（USA）
• Nervana, LLC（USA）
• ReShape Lifesciences Inc.（USA）
• SetPoint Medical（USA）
• Soterix Medical Inc.（USA）
• tVNS Technologies GmbH（Germany）
• Parasym Ltd.（UK）
• Cerbomed GmbH（Germany）
• MicroTransponder Inc.（USA）
• NeuroSigma, Inc.（USA）
• BioElectronics Corporation（USA）
• Nexstim Plc（Finland）

结论与建议

Vagus Nerve Stimulation Market size was valued at USD 550.15 Million in 2024 and is poised to grow from USD 595.81 Million in 2025 to USD 1127.55 Million by 2033, growing at a CAGR of 8.3% during the forecast period (2026-2033).

The vagus nerve stimulation (VNS) market is experiencing significant growth driven by a combination of influential factors. The increasing elderly population, advancements in technology, and rising demand for VNS as an adjunct therapy are key contributors. The surge in chronic conditions such as epilepsy and migraines, coupled with the unmet medical needs within these areas, further fuels market expansion. The growth is also enhanced by the prevalence of neurological and lifestyle-related disorders, as well as research funding supporting innovative development. Furthermore, a shift towards less invasive surgical options bolsters market potential. The efficacy of VNS in managing conditions like epilepsy and depression positions it as a pivotal therapeutic avenue, despite recent procedural volume challenges related to pandemic restrictions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Vagus Nerve Stimulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Vagus Nerve Stimulation Market Segments Analysis

Global Vagus Nerve Stimulation Market is segmented by Product Type, Application, Biomaterial, End User and region. Based on Product Type, the market is segmented into Implantable VNS Devices and External VNS Devices. Based on Application, the market is segmented into Epilepsy, Depression, Migraine and Others. Based on Biomaterial, the market is segmented into Metallic, Ceramics and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics and Ambulatory Surgical Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Vagus Nerve Stimulation Market

The increasing prevalence of neurological disorders among the aging population is significantly stimulating the demand for advanced therapeutic solutions such as Vagus Nerve Stimulation (VNS). As older adults face a higher risk of developing these conditions, there is a pressing need for effective interventions that can improve their overall well-being and quality of life. This trend underscores the importance of innovative treatments like VNS, which offer promising alternatives for managing symptoms and enhancing the functional capabilities of individuals suffering from neurological challenges. Consequently, the Vagus Nerve Stimulation market is experiencing robust growth as it responds to these evolving healthcare needs.

Restraints in the Vagus Nerve Stimulation Market

The Vagus Nerve Stimulation market faces significant restraints due to the high costs associated with the implantation procedures and the ongoing maintenance of the devices. These expenses can create substantial financial barriers for both patients and healthcare systems, potentially limiting access to this treatment option for individuals who could benefit from it. The economic implications of these costs may hinder widespread adoption and utilization of VNS therapies, as not all patients can afford the necessary procedures and subsequent upkeep. This financial strain is a critical factor that could impact the growth and acceptance of the Vagus Nerve Stimulation market overall.

Market Trends of the Vagus Nerve Stimulation Market

The Vagus Nerve Stimulation (VNS) market is witnessing a significant trend toward non-invasive solutions, driven by growing consumer demand for accessible and patient-friendly treatment options. These innovative devices present major advantages by mitigating the discomfort and risks associated with invasive procedures, thus broadening the demographic of potential users. As healthcare providers seek to enhance patient experiences and outcomes, non-invasive VNS technologies are becoming increasingly integrated into treatment protocols for various neurological and psychiatric conditions. This rising acceptance not only fosters greater patient compliance but also boosts market growth, establishing a more inclusive landscape for VNS therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Vagus Nerve Stimulation Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Implantable VNS Devices
• External VNS Devices

Global Vagus Nerve Stimulation Market Size by Application & CAGR (2026-2033)

• Market Overview
• Epilepsy
• Depression
• Migraine
• Others

Global Vagus Nerve Stimulation Market Size by Biomaterial & CAGR (2026-2033)

• Market Overview
• Metallic
• Ceramics
• Others

Global Vagus Nerve Stimulation Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Global Vagus Nerve Stimulation Market Size & CAGR (2026-2033)

• North America (Product Type, Application, Biomaterial, End User)
  • US
  • Canada
• Europe (Product Type, Application, Biomaterial, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Biomaterial, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Biomaterial, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Biomaterial, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• LivaNova PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ElectroCore, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cyberonics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroPace, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aleva Neurotherapeutics SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioControl Medical (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inspire Medical Systems, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nervana, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ReShape Lifesciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SetPoint Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Soterix Medical Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• tVNS Technologies GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parasym Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cerbomed GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroTransponder Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroSigma, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioElectronics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nexstim Plc (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations